In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for ...

The moderate to severe atopic dermatitis market is experiencing strong growth driven by rising global prevalence and heightened awareness, fueling demand for advanced treatments. Breakthroughs in ...

In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for ...

An artificial intelligence model has been developed to objectively evaluate eczema severity from smartphone photos uploaded ...

Real-world data from Australian patients show that upadacitinib demonstrates strong efficacy in treating atopic dermatitis, ...

Researchers reported key differences in atopic dermatitis presentation across racial groups and steps clinicians can take to ...

A team of researchers from Keio University School of Medicine, Kyoto Prefectural University of Medicine, and Teikyo ...

SAN DIEGO — Patients with atopic dermatitis (AD) are at a significantly ... excess risk is likely due to “a combination of biological, treatment-related, and behavioral factors.” ...

In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...

Discover a study that where results demonstrated significantly greater improvement in the ivarmacitinib groups compared to ...

Researchers have developed an AI model that objectively evaluates atopic dermatitis (AD) severity using smartphone images ...

The mainstay treatment for mild AD has traditionally ... Because psychological stress may exacerbate atopic dermatitis, psychotherapy may help alleviate AD in selected patients.